Diabetes mellitus (DM) is present among 25--35% of patients hospitalized for acute myocardial infarction (AMI) and confers a poor prognosis ([@B1]--[@B4]). Although A1C assessment is recommended for patients with DM hospitalized for an acute illness ([@B5]), whether inpatient A1C assessment impacts DM management during AMI remains unclear. We studied patients with DM in a multicenter AMI registry to evaluate the frequency of A1C assessment and its relationship with glucose therapy intensification (GTI) at discharge.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Patient population {#s2}
------------------

The Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients\' Health Status (TRIUMPH) study is a prospective AMI registry at 24 U.S. hospitals ([@B6]). In this analysis, patients with known DM (self-reported or documented in the chart) or those on glucose-lowering drugs on admission were included.

Data definitions {#s3}
----------------

Patients were considered to have clinical A1C if measured during hospitalization or obtained in the preceding 3 months. Patients consenting to TRIUMPH laboratory assessments also had A1C measured separately (laboratory A1C); these results were not available to treating clinicians. Standard A1C cut points were used (good, suboptimal, and poor control for A1C \<7, 7--9, and \>9%, respectively) ([@B7]). GTI was defined as increase in the dose of an oral antihyperglycemic agent, addition of a new antihyperglycemic agent, or ≥20% increase in daily insulin dose on discharge versus admission ([@B8]). Changing one oral agent to another was not considered GTI.

Statistical approach {#s4}
--------------------

Hierarchical Poisson regression models (controlling for clustering by hospital) were constructed to identify independent predictors of GTI. Candidate variables included demographics, factors associated with GTI in bivariate analysis, or those considered a priori as clinically important (BMI, admission glucose, mean fasting glucose, clinical A1C, intravenous insulin infusion, and admission DM medications). To evaluate whether physicians are more likely to prescribe GTI in patients with worse glycemic control when A1C is clinically available (versus when A1C levels are not known), we performed a secondary analysis in which GTI rates were compared between patients with clinical A1C versus laboratory A1C only within each glucose control subgroup (good, suboptimal, and poor).

RESULTS {#s5}
=======

A1C assessment {#s6}
--------------

Between 2005 and 2008, TRIUMPH enrolled 1,274 AMI patients with DM on admission (6% type 1, 87% type 2, and 7% unknown type). Clinical A1C assessment was performed in 886 patients (70%), and an additional 263 individuals had laboratory A1C measured. Of these 1,149 patients with known A1C levels, glycemic control was good in 419 (37%), suboptimal in 415 (36%), and poor in 315 patients (27%).

Rates and predictors of GTI {#s7}
---------------------------

Overall, 396 of 1,274 patients (31%) had GTI at hospital discharge (33% new oral medication, 37% new insulin, 5% new oral medication and insulin, 9% oral medication up-titration, and 15% insulin increase). GTI was more frequent in patients with versus without clinical A1C assessment (34 vs. 24%, *P* \< 0.001). In patients with clinical A1C, GTI rates increased with progressively worse glucose control (16, 37, and 55% with A1C levels \<7, 7--9, and \>9%, respectively; *P* \< 0.001). Moreover, physicians were more likely to prescribe GTI in patients with suboptimal or poor glucose control when A1C was clinically available ([Fig. 1](#F1){ref-type="fig"}).

![GTI stratified by subgroup of glycemic control. A1C indicates glycosylated hemoglobin.](991fig1){#F1}

Independent predictors of GTI included clinical factors (higher BMI, lack of insurance, no insulin before AMI, and fewer DM medications before AMI) and several glucose-related factors: presence of clinical A1C (relative risk 1.34 \[95% CI 1.12--1.62\]), higher A1C (1.86 \[1.40--2.45\] for A1C 7--9% and 2.45 \[1.63--3.67\] for A1C \>9%, vs. A1C \<7%), and higher fasting glucose during hospitalization (1.19 \[1.10--1.29\] per one SD increase \[52 mg/dL\]). After multivariable adjustment, presence of clinical A1C was independently associated with higher GTI rates in each glucose control subgroup, versus patients with laboratory A1C only (1.30 \[1.06--1.59\] for A1C \<7%, 2.14 \[1.13--4.04\] for A1C 7--9%, and 1.78 \[1.06--2.97\] for A1C \>9%; interaction *P* = 0.30).

CONCLUSIONS {#s8}
===========

Although guidelines recommend A1C assessment for all hospitalized patients with DM (if not recently measured) ([@B5]), we found that only 70% of AMI patients with DM had A1C levels measured clinically. When assessed, nearly two-thirds of patients with DM had suboptimal or poor long-term glycemic control, but only a minority underwent intensification of their glucose-lowering therapy by hospital discharge. Of note, clinical A1C assessment was strongly and independently associated with GTI during AMI hospitalization, especially in patients with suboptimal and poor glucose control.

Clinical implications {#s9}
---------------------

Although this analysis shows modest improvement in A1C assessment compared with earlier data ([@B8]), nearly one in three patients with DM still do not have A1C checked during AMI hospitalization. The observed association between clinical A1C availability and higher rates of both GTI and nonpharmacologic measures ([@B8]) in patients with suboptimal and poor glucose control suggests that presence of clinical A1C may lead to important therapeutic interventions for DM management. In addition, many physicians relegate DM evaluation to the outpatient setting, but chronic DM management is not consistently addressed after hospital discharge post-AMI ([@B8],[@B9]). Although randomized trials have not demonstrated reductions in cardiovascular events with intensive glucose control ([@B10],[@B11]), better glucose control does reduce microvascular complications of DM, and optimization of A1C levels continues to be recommended by professional societies ([@B5],[@B12]). Incorporating routine A1C assessment as part of in-hospital care for AMI patients with DM represents an opportunity to emphasize individualized, patient-centered DM management during AMI hospitalization that may improve transition to the outpatient setting, and potentially reduce long-term DM-related complications.

Limitations {#s10}
-----------

Only patients with established DM and AMI were included in this study, so its implications cannot be extrapolated to patients with prediabetic states or newly diagnosed DM, and generalizability of findings to other hospitalized patients is unknown. Information about GTI during the immediate postdischarge period was not available, and some patients may have received GTI during early outpatient follow-up. Furthermore, the impact of therapeutic intensification on clinical outcomes remains unclear, as our study was not designed to address this question.

Summary {#s11}
-------

Nearly two-thirds of hospitalized AMI patients with DM have suboptimal or poor long-term glycemic control, but only a minority receives intensification of glucose-lowering therapy at discharge. Inpatient A1C assessment is strongly associated with higher rates of GTI, particularly when glycemic control is suboptimal or poor. Future studies should evaluate whether clinical outcomes are affected by intensification of glucose-lowering therapy after AMI in patients with poor glucose control.
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